Program Description
Alzheimer disease (AD) is an irreversible, progressive neurodegenerative disorder and is the 6th leading cause of death in the United States. Currently, AD is diagnosed based on clinical signs and symptoms due to neurodegeneration believed to be caused by the accumulation of amyloid-beta peptides and neurofibrillary tangles (NFTs). Traditional therapies are associated with slight improvements in symptoms by delaying the destruction of neurons. New and emerging therapies aim to modify disease progression by reducing the formation of the plaques and NFTs to enhance cognition. The overall burden of AD is substantial to patients, their caregivers, and the healthcare system. It was estimated that AD and other dementias cost $200 billion in the United States in 2021, and that cost is expected to reach $1.1 trillion by 2050. As data for disease-modifying agents in AD emerge, it is crucial for managed care professionals to develop medication utilization and reimbursement strategies that promote early diagnosis and treatment before neuronal damage occurs as well as reduce disparities and enhance access to these therapies to enhance outcomes and lower costs for patients, caregivers, and the healthcare system.
Target audience: Managed care pharmacists, specialty pharmacists
Type of activity: Application
Release date: September 1, 2022
Expiration date: February 29, 2024
Time to complete activity: 2.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology, the progression of Alzheimer disease (AD), and the role of amyloid plaques as a target for treatment.
- Explore recent clinical findings and emerging data for disease-modifying agents in the treatment of AD.
- Analyze the economic burden of AD and disease management programs that aim to reduce healthcare costs and improve quality of life for patients with AD.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
